Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. - Wikidata - awgldk - TriplyDB

Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients.

Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients.

http://www.wikidata.org/entity/Q46058156

about

Tumor-intrinsic and -extrinsic roles of c-Kit: mast cells as the primary off-target of tyrosine kinase inhibitors Trial Watch Functional Significance of CD57 Expression on Human NK Cells and Relevance to Disease Microenvironmental Targets in Sarcoma Granzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia.Targeted therapy for cancer: the gastrointestinal stromal tumor model.Oncogene withdrawal engages the immune system to induce sustained cancer regression.Immune cells in primary and metastatic gastrointestinal stromal tumors (GIST).Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial.An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation.Preservation of immune function in cervical cancer patients during chemoradiation using a novel integrative approach.Recognition of tumors by the innate immune system and natural killer cells.TNF-α and tumor lysate promote the maturation of dendritic cells for immunotherapy for advanced malignant bone and soft tissue tumors.Daily intake of probiotics with high IFN-γ/IL-10 ratio increases the cytotoxicity of human natural killer cells: a personalized probiotic approach.Natural killer (NK) cell profiles in blood and tumour in women with large and locally advanced breast cancer (LLABC) and their contribution to a pathological complete response (PCR) in the tumour following neoadjuvant chemotherapy (NAC): differentia Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido.PDL1 expression is an independent prognostic factor in localized GIST.Targeted therapy in Ewing sarcoma.Exploiting antitumor immunity to overcome relapse and improve remission duration.Increased NK Cell Maturation in Patients with Acute Myeloid Leukemia Inhibition effect of Peg-IFNα-2b and Imatinib alone or combination on imatinib-resistant gastrointestinal stromal tumors cell lines.The synergistic interaction between the calcineurin B subunit and IFN-γ enhances macrophage antitumor activity.Trial watch: Prognostic and predictive value of the immune infiltrate in cancer Natural killer cells in non-hematopoietic malignancies Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate.Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR(+) NK cell levels correlate with disease outcome.Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go?Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib Noncanonical roles of the immune system in eliciting oncogene addiction Blood neutrophil-to-lymphocyte ratio is prognostic in gastrointestinal stromal tumor.Combination of PLR, MLR, MWR, and Tumor Size Could Significantly Increase the Prognostic Value for Gastrointestinal Stromal Tumors.Progressive natural killer cell dysfunction associated with alterations in subset proportions and receptor expression in soft-tissue sarcoma patients.Natural Killer Cell Diversity in Viral Infection: Why and How Much?Anticancer immunochemotherapy using adjuvants with direct cytotoxic effects.Clinical significance of the preoperative platelet count and platelet-to-lymphocyte ratio (PLT-PLR) in patients with surgically resected non-small cell lung cancer.KIT oncogene inhibition drives intratumoral macrophage M2 polarization.Application of tissue-specific NK and NKT cell activity for tumor immunotherapy.NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients.Immune parameters affecting the efficacy of chemotherapeutic regimens.Combining immunotherapy and targeted therapies in cancer treatment.

P2860

Q24306212-0067A731-7A60-4637-8506-42D69106D4BB Q24618653-D992D020-2E8F-4727-86E4-18297C601DAE Q27022458-621F090E-D150-45DB-9868-72657E8E2C90 Q28081400-07CE1770-5ECD-4C15-BF40-98307BFA4C25 Q30554443-9AB325AF-4655-4C73-B010-D0F5BAB9BD06 Q33807742-1EAB983C-3382-47FF-84D8-D305BA9CB164 Q33987633-ABE308D7-7F74-43A9-81EC-BBFD07AA3ADE Q34028872-AC7A3E84-A7D9-4279-A6D3-39AFC79E6892 Q34083140-9EB1E8AB-D997-43C6-830C-1E8778F3D32F Q34361976-B5A2BACC-2C23-4995-845A-3A62A8E6C71C Q34441128-017E5255-2330-472B-93A6-E0A10A52796D Q34496462-755B5D06-F48E-4E40-993B-78174E505D23 Q34541424-B61C44DA-2553-4884-BC48-18E00E6BA923 Q35156027-D368108E-1969-4306-BBE5-8EF8DAB48AC7 Q35743162-121F830A-46F9-415F-B769-4CFED08C624F Q35753251-5352E26C-2EC6-4189-A1CA-BFEEB2A49920 Q35798839-9014A69B-4355-48F3-B5AB-76AF96E353CB Q36011879-83DB91FD-F76F-4B87-996B-F992C850276D Q36044604-41DFFDAE-4D8A-48DF-AD9E-C2DB7E4CDEF4 Q36256263-33C5D425-DCE9-4CC1-B857-F107C0D56677 Q36261782-724869B8-F11B-45CB-B5FF-91DB4387711B Q36346996-DC756663-A541-4AAB-8D7B-7E62B89C9CC1 Q36456483-7D60AFF9-3DF9-4B31-B00B-0D0C60D56C5F Q36486204-24CB9186-8ECA-4ABC-AABB-C6B3C7EEC34F Q36694926-E8DC433B-99EC-4D9B-AFA1-E9ABDF58F1E3 Q36694931-A7CD428F-8CFB-4E74-ABAB-30285117DC7C Q36821572-30D6878C-7568-4463-A440-1D506BB50462 Q36866959-96EA1006-BE4B-4914-8F72-643BB004CF8F Q36931816-76736397-79AA-4E5D-A20B-61EDA3359AAA Q36979386-869DC721-17C3-48AB-92C7-684B48150DF0 Q37206680-25B54277-CD4C-4216-8435-A8B7D46E9558 Q37222064-7A58C583-EA85-42A2-9C6F-1AC617C1D9C6 Q37252674-C9F59EF8-D7EC-4E51-9F40-F5138BC0C303 Q37286646-807A99A5-B738-490D-B9A0-CEB10046361E Q37392676-A132EA87-2B39-4A96-855D-E7CE11EDC099 Q37397817-A58B145C-C655-4A21-9D9E-D775492731A5 Q37439660-020C865F-1C8A-4AD3-B6FC-F6359D3D6A83 Q37616478-5E069597-0F71-49D4-95F1-3EE897F28270 Q37848665-AA6DF34F-EB58-4FA1-98D6-3418753DE387 Q37995939-82229325-8E98-4BD8-BBA2-87F8536AAB8C

P2860

Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients.

http://www.wikidata.org/entity/Q46058156

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Natural killer cell IFN-gamma ...... tromal tumor-bearing patients.

@en

Natural killer cell IFN-gamma ...... tromal tumor-bearing patients.

@nl

type

label

Natural killer cell IFN-gamma ...... tromal tumor-bearing patients.

@en

Natural killer cell IFN-gamma ...... tromal tumor-bearing patients.

@nl

prefLabel

Natural killer cell IFN-gamma ...... tromal tumor-bearing patients.

@en

Natural killer cell IFN-gamma ...... tromal tumor-bearing patients.

@nl

P1433

Q46058156-A61F8B03-E6C3-48D9-860F-B3A2C097E820

P1476

Q46058156-290EE6C1-94E5-4D76-BACE-C372AC92C21E

P2093

Q46058156-0CBFAC94-576E-4F07-ADD1-E68B9DA1ACDB

Q46058156-0EB2C037-0BFD-4758-86C4-96A62BED2B55

Q46058156-2DB8974E-3A88-4265-8A8A-D0C7D4F94D38

Q46058156-509F3311-A73F-4284-A00E-31E5241D380F

Q46058156-55A78EB2-99CD-4944-945E-C5B02FDA74B7

Q46058156-69360C42-6C39-43D8-BBF0-80D3931AAC40

Q46058156-F6D83A56-5C14-42E3-9920-4B5A04B39092

Q46058156-FC9B9F16-393D-4F20-B887-E7BE0CC6BF63

P304

Q46058156-C91BE1FA-C88A-41EA-9EA7-FACFBD184601

P31

Q46058156-E112AC68-E1E4-4801-BAD9-01C829B450B7

P356

Q46058156-FB3AE9B6-ADB1-4E6C-9298-27874FF0C3FA

P407

Q46058156-474E0DC0-0572-4AD4-850D-3DA477E4535E

P433

Q46058156-BF1EF70A-0FFB-41C1-BE64-BC3B14A8AD8B

P478

Q46058156-547AF297-2CF0-4DEE-AD08-029CF40B7650

P50

Q46058156-0264EB7A-3D21-4D3E-A930-672302440C2C

Q46058156-4BDC5809-D6BA-42B6-8873-EB63D7E4405D

Q46058156-729E15EF-E480-4A11-B928-10F9E1F566E1

Q46058156-7B1E3355-314A-4112-A33A-3A25AD6DEBB0

Q46058156-7BB16F39-5517-411A-9292-4246A4E4AD1C

Q46058156-97858D07-CDDC-4995-AB48-B79A86607A0E

Q46058156-F8204E98-4F60-443C-813B-D66F62952E4D

Q46058156-FAC230B8-1E22-4092-91F8-8BAD5AC251EB

P577

Q46058156-FD60BDDA-77FA-4DD9-8B6D-E1231FE6F921

P5875

Q46058156-DA5E8AE9-43DE-4FAA-8DEA-993E7FECFE93

P698

Q46058156-367E5945-5178-4184-966D-7603C699B985

P921

Q46058156-FD797704-5E73-435E-B7FA-C21F17259D5A

P356

0008-5472.CAN-08-3807

P1433

Cancer Research

P1476

Natural killer cell IFN-gamma ...... tromal tumor-bearing patients.

@en

P2093

Caroline Flament

http://www.w3.org/2001/XMLSchema#string

Christophe Borg

http://www.w3.org/2001/XMLSchema#string

Cédric Ménard

http://www.w3.org/2001/XMLSchema#string

Céline Nonn

http://www.w3.org/2001/XMLSchema#string

François Ghiringhelli

http://www.w3.org/2001/XMLSchema#string

Jean-François Emile

http://www.w3.org/2001/XMLSchema#string

Julien Taïeb

http://www.w3.org/2001/XMLSchema#string

Nicolas F Delahaye

http://www.w3.org/2001/XMLSchema#string

P304

3563-3569

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-08-3807

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P50

Laurence Zitvogel

Nathalie Chaput

François Ghiringhelli

Caroline Flament

Stefan Michiels

Caroline Robert

P577

2009-04-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24262783

http://www.w3.org/2001/XMLSchema#string

P698

19351841

http://www.w3.org/2001/XMLSchema#string

P921